{
    "id": 18259,
    "fullName": "DLL3 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "DLL3 over exp indicates an over expression of the Dll3 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 10683,
        "geneSymbol": "DLL3",
        "terms": [
            "DLL3",
            "SCDO1"
        ]
    },
    "variant": "over exp",
    "createDate": "02/17/2016",
    "updateDate": "04/02/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6741,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Rovalpituzumab Tesirine treatment resulted in complete response or partial response in 55% (12/22) and clinical benefit in 91% (20/22) of DLL3 positive lung small cell carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr LBA8505)).",
            "molecularProfile": {
                "id": 18587,
                "profileName": "DLL3 over exp"
            },
            "therapy": {
                "id": 3544,
                "therapyName": "Rovalpituzumab Tesirine",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5803,
                    "pubMedId": null,
                    "title": "Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).",
                    "url": "http://abstracts.asco.org/176/AbstView_176_162941.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19924,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (TRINITY), Rovalpituzumab Tesirine treatment resulted in moderate antitumor activity in patients with small cell lung cancer overexpressing DLL3, including an objective response rate of 14.3% (34/238) and a median overall survival of 5.7 months (PMID: 31506387; NCT02674568).",
            "molecularProfile": {
                "id": 18587,
                "profileName": "DLL3 over exp"
            },
            "therapy": {
                "id": 3544,
                "therapyName": "Rovalpituzumab Tesirine",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17586,
                    "pubMedId": 31506387,
                    "title": "Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31506387"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4562,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rovalpituzumab Tesirine treatment resulted in sustained tumor regression in PDX models of small cell lung carcinoma with elevated levels of Dll3 protein (PMID: 26311731).",
            "molecularProfile": {
                "id": 18587,
                "profileName": "DLL3 over exp"
            },
            "therapy": {
                "id": 3544,
                "therapyName": "Rovalpituzumab Tesirine",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4615,
                    "pubMedId": 26311731,
                    "title": "A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26311731"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4563,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rovalpituzumab Tesirine treatment resulted in sustained tumor regression in PDX models of large cell neuroendocrine carcinoma with elevated levels of Dll3 protein (PMID: 26311731).",
            "molecularProfile": {
                "id": 18587,
                "profileName": "DLL3 over exp"
            },
            "therapy": {
                "id": 3544,
                "therapyName": "Rovalpituzumab Tesirine",
                "synonyms": null
            },
            "indication": {
                "id": 50872,
                "name": "large cell neuroendocrine carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4615,
                    "pubMedId": 26311731,
                    "title": "A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26311731"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 18587,
            "profileName": "DLL3 over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 17046,
                    "name": "Rovalpituzumab Tesirine",
                    "profileName": "DLL3 over exp"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}